12 Baillie Gifford Recursion Pharmaceuticals Trades
Baillie Gifford's position in Recursion Pharmaceuticals is currently worth $199 Million. That's 0.15% of their equity portfolio (91st largest holding). The investor owns 10.45% of the outstanding Recursion Pharmaceuticals stock. The first Recursion Pharmaceuticals trade was made in Q2 2021. Since then Baillie Gifford bought shares four more times and sold shares on seven occasions. The investor's estimated purchase price is $641 Million, resulting in a loss of 69%.
Avg closing price
Price range
Sold 0.5% shares (-112 Thousand shares)
Q1 2024
Avg closing price
$11.14
Price range
$9.13
-
$15.52
Sold 1.5% shares (-372 Thousand shares)
Q4 2023
Avg closing price
$7.13
Price range
$5.09
-
$10.79
Sold 2.2% shares (-546 Thousand shares)
Q3 2023
Avg closing price
$9.98
Price range
$6.59
-
$15.86
Sold 0.2% shares (-37.9 Thousand shares)
Q2 2023
Avg closing price
$7.00
Price range
$4.56
-
$9.94
Increased shares by 1.3% (+315 Thousand shares)
Q1 2023
Avg closing price
$7.93
Price range
$6.42
-
$9.64
Increased shares by 14.9% (+3.23 Million shares)
Q4 2022
Avg closing price
$9.81
Price range
$7.16
-
$12.70
Sold 0.1% shares (-11 Thousand shares)
Q3 2022
Avg closing price
$10.13
Price range
$7.83
-
$13.60
Sold 1.7% shares (-376 Thousand shares)
Q2 2022
Avg closing price
$6.69
Price range
$5.04
-
$9.26
Sold 0.6% shares (-142 Thousand shares)
Q1 2022
Avg closing price
$10.63
Price range
$6.16
-
$18.03
Increased shares by 0.3% (+61.8 Thousand shares)
Q4 2021
Avg closing price
$18.82
Price range
$16.14
-
$21.86
Increased shares by 19.1% (+3.54 Million shares)
Q3 2021
Avg closing price
$28.34
Price range
$19.03
-
$41.33
New holding (+18.5 Million shares)
Q2 2021
Avg closing price
$29.60
Price range
$21.06
-
$37.42
